Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Liquidia in a ...

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares ...

Learn about our editorial policies The required rate of return (RRR) and the cost of capital are key fundamental metrics in finance and investing. These measures—which vary in scope, perspective ...

Working capital is the money used to cover all of a company's short-term expenses, including inventory, payments on short-term debt, and day-to-day expenses—called operating expenses.

Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($1.83) for the year. Lifesci Capital has a “Outperform” rating and a $20.00 price target on the stock.

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Oil & Gas, Technology and Basic Materials ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...